Loss-of-function mutations ensure that response to immune checkpoint therapy is NOD2 be denied

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Programmed cell death protein 1 (PD-1) blockade is a cornerstone of cancer immunotherapy.
• Predictive biomarkers for PD-1 blockade response are crucial for optimizing patient selection.
• Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is an intracellular pattern recognition receptor involved in immune responses.

Purpose of the Study:

• To investigate the association between loss-of-function mutations in the NOD2 gene and clinical response to PD-1 blockade monotherapy in cancer patients.

Main Methods:

• Retrospective analysis of patient data from clinical trials involving PD-1 blockade.
• Genomic sequencing to identify NOD2 mutations.
• Correlation analysis between NOD2 mutation status and objective response rate (ORR).

Main Results:

• Patients with loss-of-function NOD2 mutations exhibited a significantly higher ORR to PD-1 blockade monotherapy compared to those with wild-type NOD2.
• NOD2 mutation status was identified as an independent predictor of response.

Conclusions:

• Loss-of-function mutations in NOD2 may serve as a predictive biomarker for response to PD-1 blockade immunotherapy.
• Targeting or considering NOD2 status could enhance the efficacy of PD-1 blockade in specific cancer patient populations.